Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The companys commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The companys pre clinical and clinical stage products consist of OTEZLA for the treatment of psoriatic arthritis, psoriasis, and ankylosing spondylitis; CC-122 and CC-220 to treat hematological and solid tumor cancers; cellular therapies, such as PDA-001 and PDA-002 for Crohns and peripheral arterial diseases; CC-486, to treat MDS, AML, and solid tumors; Sotatercept and ACE-536 for the treatment of anemia in patients with rare blood disorders; CC-223 and CC-115 for lymphomas, hepatocellular, and prostate cancers; and CC-292 for the treatment of chronic lymphocytic leukemia and lymphomas. It has strategic drug discovery collaboration with Abide Therapeutics to enhance the treatment paradigm for patients with immune disorders. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Taking Stock24 Apr 2014, 4:07 pmGreat Speculations Quarterly earnings season often brings surprises, some disappointing and others quite rewarding. Apple (AAPL-$569), my largest position, delighted its fans with a 7% profit increase together with increases in its dividend and stock buyback program and a seven to one stock split. With the largest market cap of all, it attracts much attention […] The post Taking Stock appeared ...
Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog24 Apr 2014, 1:04 pmCelgene Earnings Grow Year Over Year in Q1 - Analyst Blog
Celgene Earnings Grow Year Over Year in Q124 Apr 2014, 10:29 amProduct sales increased at Celgene (CELG) in the quarter.
Jim Cramer's Stop Trading: CELG24 Apr 2014, 9:33 amNEW YORK (TheStreet) -- Celgene is a "very, very cheap" stock, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Cramer's Stop Trading" segment Thursday The biotechnology stock, an AAP holding, missed revenue estimates but beat earnings expectations. Celgene also saw sales of Revlimid, its number one-selling drug, come in lower than expected. Cramer noted ...
Stock Market News for April 24, 2014 - Market News24 Apr 2014, 9:05 amStock Market News for April 24, 2014 - Market News
Stock Market News for April 24, 201424 Apr 2014, 7:14 amBenchmarks ended lower on Wednesday following disappointing corporate results and economic data
3 Reasons Celgene Will Bounce Back This Year24 Apr 2014, 3:01 amCelgene's stock has suffered with biotech's fall this year, but this top health-care stock's poised for long-term success.
Will Celgene (CELG) Miss this Earnings Season?23 Apr 2014, 1:30 pmCelgene Corporation (CELG) is set to report first quarter 2014 results on Apr 24 before market opens.
Ken Fisher's Top Increases of the First Quarter22 Apr 2014, 4:36 pmBy Monica Wolfe. Read more » » Check out Ken Fisher Stock Picks » Download GuruFolio Report of Ken Fisher (Updated on 04/24/2014) Related Stocks: CHL , BIIB , RYCEY , CELG , KB ,
Biotech Stock Mailbag: Celgene, IsoRay, Northwest Bio, Bubble Worries4 Apr 2014, 5:31 amNEW YORK (TheStreet) -- This week's Biotech Stock Mailbag opens with an email from Paul S. about Celgene : Why is Celgene down so much? This was a great stock last year but not so this year even though the news from the company has been good. Can you explain what's going on, please? Let's consult a chart of Celgene's performance relative to the other big-cap biotech stocks:CELG data by YCharts ...